NCT05838066
- Conditions
- Breast Diseases, Breast Neoplasms, First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer, +4 more
- Locations
-
- Clinical Trials Information Group Beijing, chaoyang, China
Clinical trial condition
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Explore clinical trials studying First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer. Study availability and eligibility vary by location and protocol.
1 public trial
1 recruiting study